AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

Oxybutynin Chloride

9 registrations across 2 African markets— 6 active

Markets with Oxybutynin Chloride

Recent registrations

Brand / ProductMarketHolderStatusExpires
OXYSPAS🇿🇦South AfricaCipla Medpro (Pty) LtdsuspendedJul 2025
LYRINEL 5 mg🇿🇦South AfricaJanssen Pharmaceutica (Pty) LtdsuspendedOct 2022
LYRINEL 10 mg🇿🇦South AfricaJanssen Pharmaceutica (Pty) LtdsuspendedOct 2022
LENDITRO🇿🇦South AfricaPharmacare Limited û WoodmeadactiveJan 1900
DITROPAN🇿🇦South AfricaPharmaco Distribution (Pty) LtdactiveJan 1900
OXYREST🇿🇦South AfricaiPharma (Pty) LtdactiveJan 1900
CIPLA-OXYBUTYNIN CHLORIDE🇿🇦South AfricaCIPLA LIFE SCIENCES (PTY) LTDactiveJan 1900
MYLAN OXYBUTYNIN 5🇿🇦South AfricaViatris South Africa (Pty) LtdactiveJan 1900
SPASTYNIN
Extended Release Tablet
🇹🇿TanzaniaUNIQUE PHARMACEUTICAL LABORATORIES (A Div. of J. B. Chemicals & Pharmaceuticals Ltd)active

Oxybutynin Chloride in Africa — Regulatory Overview

Oxybutynin Chloride is registered across 2 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 6 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.